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Abstract
Background: Platelet activation appears to play an important role in thromboembolic com-
plications of infective endocarditis (IE). Mean platelet volume (MPV) is a potentially useful 
marker of platelet activity and a quick and easy determinant of thrombotic risk. Hence the aim 
of this study was to investigate the baseline platelet volume indices (MPV and platelet distribu-
tion width [PDW]) in IE patients who developed embolic events in the follow-up period and 
who did not.
Methods: The study group consisted of 76 consecutive patients (female: 55, male: 21, mean 
age: 26 years old, ranged: 8–64 years) with definite IE according to Duke Criteria. Thirty four 
healthy subjects, who were age and gender adjusted, served as the control group. The mean 
duration of hospital stay was 44 days.
Results: Among the IE patients, 13 (13/76, 17.1%) had major embolic events. Significantly 
larger vegetations were observed in patients with embolic events as compared to non-embolic 
group (1.4 vs. 1.0 cm, p = 0.03). MPV at hospital admission was higher in patients who had 
embolic events in the follow-up period compared to both those who did not and the control sub-
jects (10.62 ± 1.13 vs. 9.25 ± 0.97 and 8.93 ± 0.82 fL, p < 0.001, respectively). Similarly, 
the patients with embolic events had increased PDW compared to the non-embolic ones and the 
control group (16.31 ± 2.42 vs. 14.35 ± 1.97 and 14.04 ± 1.82%, p < 0.001, respectively).
Conclusions: The present study demonstrated that IE patients with embolic events had in-
creased MPV and PDW values, compared to non-embolics. Future prospective studies with 
standardized measurements may clarify the clinical role of platelet volume indices in thrombo-
embolic complications of IE. (Cardiol J 2015; 22, 1: 37–43)
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Introduction
It has long been known that thromboembolic 
events are common and severe complications of in-
fective endocarditis (IE) which occur in 20% to 43% 
of cases, with the majority as cerebral emboli [1–3]. 
This wide range of complications points to the 
heterogeneity of the disease and the critical need 
for baseline risk stratification in order to focus 
aggressive management toward a high-risk group 
of patients. The predictive role of clinical and echo-
cardiographic parameters on the subsequent risk 
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of embolism was well investigated [4–7]. However, 
the interrelations between the biomarkers of platelet 
activity and the risk of embolic events have not been 
well studied in a large prospective patient population 
with definite IE. Mean platelet volume (MPV) is 
a potentially useful marker of platelet activity and 
a quick and easy determinant of thrombotic risk 
[8–10]. Platelet distribution width (PDW), another 
platelet activation marker, shows the variability in 
platelet size. Hence the aim of this study was to inve-
stigate the baseline platelet volume indices (MPV and 
PDW) in IE patients who developed embolic events 
in follow up period and who did not.
Methods
Seventy-six consecutive patients (female: 55, 
male: 21, mean age: 26 years old, ranged: 8–64 
years) admitted to the Department of Cardiology in 
Türkiye Yüksek İhtisas Hospital with the diagnosis 
of definite IE according to Duke criteria [11] were 
included in this study. IE was diagnosed if one of 
these criteria was present; (1) histopathologic 
evidence of endocarditis; (2) persistent positive 
blood cultures, excluding other potential sources 
of bacteremia, and a new regurgitant murmur or 
predisposing heart disease; and (3) negative or 
intermittently positive blood cultures plus fever 
in the presence of a new regurgitant murmur 
and microvascular or immunologic phenomena. 
Exclusion criteria were: patients with a history of 
thromboembolic events before hospital admittance, 
patients who had prosthetic heart valves, patients 
under platelet-inhibitors treatment, patients with 
hematological disorders or cancer and patients with 
a cerebral hemorrhage or uncertainty about the 
diagnosis of an embolic event. Thirty four healthy 
subjects who were age and gender adjusted (fe-
male: 24, male: 10, mean age: 24 years old, ranged: 
10–63 years) served as the control group. The 
study protocol was approved by the institutional 
Ethics Committee and informed consent was given 
by all patients and control subjects.
The patients were hospitalized and prospectively 
followed in our clinic until discharge, by a team com-
posed of cardiologists, infectious disease specialists, 
cardiac surgeons, and neurologists involved in man-
agement of the patients. Blood cultures and initial 
clinical evaluation were systematically performed 
in all patients at baseline (before the initiation of 
adequate antibiotic therapy). Antibiotic therapy was 
started immediately after diagnosis. Blood samples 
for hematologic variables and platelet volume indices 
were drawn at 8.00 to 10.00 a.m. hospital admis-
sion. Transthoracic and transesophageal echocar-
diographic examinations were performed within 
3 days of initiation of antimicrobial therapy. The mean 
duration of hospital stay was 44 days. All patients 
were observed daily by cardiology and infectious 
disease specialists, and additional consultations 
were secured when indicated. The diagnosis of an 
embolic event was based on physical examination, 
cerebral computed tomography, peripheral Doppler 
ultrasonographic investigation or angiography. Micro-
vascular emboli such as cutaneous microinfarctions or 
immune complex phenomena were not regarded as 
embolus. Thirteen (17.1%) patients were diagnosed 
to develop either a cerebral (n = 7), pulmonary 
(n = 2), renal (n = 1) or a major peripheral (n = 3, 
of which 2 popliteal and 1 femoral artery) embolic 
event during the in hospital follow-up period. The 
remaining 63 (82.9%) patients with IE did not have 
any embolic events.
Transthoracic 2-dimensional and color flow 
Doppler echocardiography was performed in all 
patients using ultrasound equipment (Toshiba 
SSH160A) with commercially available 2.5-MHz 
transducers. Transesophageal examination was 
performed within 3 days of initiation of antimicro-
bial therapy with the use of a 5-MHz phased — ar-
ray transducer. All echocardiographic studies were 
recorded on super-VHS videotape for subsequent 
independent review and analyzed by 2 echocardio-
graphers who were unaware of the clinical status 
of the patients. In case of disagreement, a third 
examiner was consulted. The presence and charac-
teristics of vegetations were evaluated according 
to transesophageal echocardiography. Valvular ve-
getation was defined as an oscillating or fixed mass 
associated with a valve or its supporting apparatus, 
distinct in echogenic structure, and with motion 
independent from the remainder of the involved 
leaflet [12]. The lesion had to be detectable throu-
ghout the complete cardiac cycle. Diffuse valvular 
irregularities or valvular thickenings were not 
regarded as vegetation. Echocardiographic data in-
cluded the presence, maximal length, mobility and 
being pedunculated or sessile of vegetation. Me-
asurements of vegetation length were performed 
in various planes, and maximal length was used. In 
the presence of multiple vegetations, the largest 
length was used for analysis. The vegetation was 
evaluated as immobile when it was fixed with no 
detectable independent motion or had a fixed base 
but with a minimal motion of the free edge.
Blood samples at hospital admission were 
drawn from the antecubital vein by careful ve-
nipuncture using a 21-gauge needle attached to 
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a sterile syringe at 8.00 to 10.00 a.m. Platelet 
volume indices were measured in blood samples 
collected in dipotassium ethylenediaminetetraace-
tic acid (EDTA) containing tubes by flow cytometry 
in an automated blood cell counter (Sysmex, XT-
2000i) immediately within 60 min after sampling. 
The Sysmex XT 2000i uses the electric resistance 
detecting method (impedance technology) with 
hydrodynamic focusing [13]. Hydrodynamic focu-
sing direct current detection is a modification of 
the optical method and used for the measurement 
of red blood cell and platete. This method is to en-
close the diluted sample ejected from a nozzle with 
a circumfluent sheath fluid, to allow the sample 
to flow through the center of an aperture, and to 
detect the changes in the electric current flowing 
through the aperture. Fluorescence flow cytome-
try is used to measure white blood cells (WBC), 
differential parameters, the optical platelet count 
and the reticulocyte count. The system employs 
a 633 nm semi-conductor laser for flow cytometry 
analysis. For the measurement by flow cytometry 
of the proportional count, expressed as percent of 
the total WBC, of neutrophils, lymphocytes, mono-
cytes and eosinophils, white cells are stained with 
fluorescent dyes that bind to both DNA and RNA. 
Side scatter is employed to determine the internal 
complexity of the cell. Fluorescence and scatter 
measurements are combined to characterize white 
cell populations.
Statistical analysis
Results are expressed as mean ± standard 
deviation. Comparison of clinical and echocar-
diographic variables between patients with and 
without embolic events was performed using 
Student’s t- test for numerical variables and c2 test 
for categorical data. All patients with IE with and 
embolic events and control subjects were compared 
for MPV and PDW using the Mann-Whitney U test. 
A p value < 0.05 was considered significant.
Results
The study group consisted of 76 consecutive 
patients (female: 55, male: 21, mean age: 26 years 
old, ranged: 8–64 years) with definite IE accor-
ding to Duke Criteria. Patients with a history of 
thromboembolic events before hospital admittance 
or those who had prosthetic heart valves, or were 
being treated with platelet-inhibitors were exclu-
ded. Thirty four healthy subjects who were age and 
gender adjusted (female: 24, male: 10, mean age: 
24 years old, ranged: 10–63 years) served as the 
control group. The mean duration of hospital stay 
for patients was 44 days.
Among the 76 patients with IE included in the 
study, 13 (17.1%) developed embolic events (7 ce-
rebral, 2 pulmonary, 1 renal and 3 major peripheral) 
in follow-up period while the remaining 63 did not 
have this complication. Thirteen (17.1%) patients 
were diagnosed to develop either a cerebral (n = 7), 
pulmonary (n = 2), renal (n = 1) or a major periphe-
ral (n = 3, of which 2 popliteal and 1 femoral artery) 
embolic event during the in-hospital follow-up pe-
riod. Clinical and echocardiographic characteristics 
of patients with and without embolic events are 
shown in Table 1. Measurements of simple hema-
tological variables and causative microorganisms 
did not differ significantly between the two groups. 
Localization, mobility and attachment characte-
ristics of the vegetations were similar between 
patients with and without embolic complications. 
Although there was a trend toward a higher num-
ber of vegatations detected in those with embolic 
events, this did not reach statistical significance 
(84.6% vs. 80.9%, p > 0.05). Significantly larger 
vegetations were observed in patients with embo-
lic events as compared to the non-embolic group 
(1.4 vs. 1.0 cm, p = 0.03).
MPV at hospital admission was higher in 
patients who had embolic events in the follow-up 
period compared to both those who did not and the 
control subjects (10.62 ± 1.13 vs. 9.25 ± 0.97 and 
8.93 ± 0.82 fL, p < 0.001, respectively) (Table 2). 
Similarly, the patients with embolic events had 
increased PDW compared to non-embolic ones and 
the control group (16.31 ± 2.42 vs. 14.35 ± 1.97 
and 14.04 ± 1.82%, p < 0.001, respectively) 
(Table 2).
Discussion
The present study is the first to have a pro-
spective design, comparing the platelet volume 
indices, namely MPV and PDW, in a relatively 
large population of IE patients with and without 
thromboembolic complications. Patients who de-
veloped embolic events in follow-up period had 
significantly increased MPV and PDW values at 
admission compared to non-embolic ones. Larger 
platelets in the embolic group reflect enhanced 
platelet activity and probably identify patients at 
high thromboembolic risk. These data suggest that 
MPV is a potentially useful prognostic biomar-
ker for the risk of embolic events in IE patients. 
Although the precise biological pathways by which 
elevated MPV might influence the development 
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of embolic complications, multiple mechanisms 
may be involved. Larger platelets are metaboli-
cally more active and have greater prothrombotic 
potential with increased thromboxane-A2 and B2 
per unit volume and glycoprotein IIb/IIIa receptor 
expression [14, 15]. They show more aggregability 
in response to adenosise diposphate and decreased 
inhibition of aggregation by prostacyclin in vitro. 
Larger platelets are denser and contain more 
alpha granules which can release prothrombotic 
substances including platelet factor-4, P selectin 
and platelet-derived growth factor [15].
Some mechanisms suggested to cause syste-
mic embolism in bacterial infections are namely 
activation of blood coagulation, enhanced platelet 
activity/damage and endothelial cell injury. Pre-
vious investigations demonstrated that systemic 
bacterial infections, even in the absence of cardiac 
involvement, represent an independent risk factor 
for embolic events [16–19]. Inflammation induced 
Table 1. Clinical and echocardiographic characteristics of infective endocarditis patients with and  
without embolic events.
Embolic event (+) 
(n = 13)
Embolic event (–) 
(n = 63)
Age 28 24
Men/women 4/9 17/46
Hematologic variables:
Hematocrit [%] 35.3 ± 4.1 34.4 ± 5.2
Erythrocyte sedimentation rate [mm/h] 98 76
Platelet count [×109/L] 265.5 ± 62.4 245.6 ± 56.4
aPTT [s] 26.8 ± 4.0 31.5 ± 6.3
Fibrinogen [g/L] 6.1 ± 1.3 4.2 ± 1.5
Causative microorganisms:
Viridans streptococci 5 (38.4%) 22 (34.9%)
Group D streptococci and enterococci 2 (15.4%) 9 (14.2%)
Other streptococci 1 (7.6%) 4 (6.3%)
Staphylococci 3 (23.1%) 14 (22%)
Other microorganism 1 (7.6%) 7 (11.1%)
Undetermined 1 (7.6%) 7 (11.1%)
Vegetation detected 11 (84.6%) 51 (80.9%)
Location of vegetation:
Mitral 6 (54.5%) 27 (52.9%)
Aortic 3 (27.2%) 19 (37.2%)
Mitral and aortic 1 (9.1%) 3 (5.8%)
Tricuspid 1 (9.1%) 2 (3.9%)
Vegetation characteristics:
Size [cm] 1.4 ± 0.4* 1.0 ± 0.3
Mobile/immobile 3/8 14/49
Pedunculated/sessile 1/10 7/56
*p = 0.03 compared to embolic (–) patients; aPTT — activated partial thromboplastin time
Table 2. Platelet volume indices in infective endocarditis patients with and without embolic events and 
control subjects.
Variables Embolic event (+) 
(n = 13)
Embolic event (–) 
(n = 63)
Control group 
(n = 34)
Mean platelet volume [fL] 10.62 ± 1.13* 9.25 ± 0.97 8.93 ± 0.82
Platelet distribution width [%] 16.31 ± 2.42** 14.35 ± 1.97 14.04 ± 1.82
*p < 0.001 compared to embolic event (–) patients and control group; **p < 0.001 compared to embolic event (–) patients and control group
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procoagulant changes and endothelial cell injury 
favoring thrombosis were suggested as an explana-
tion in this setting. It was reported that, especially 
severe bloodstream bacterial infections change the 
prostacyclin-thromboxane ratio in the direction of 
thrombosis and induce the production of cytokines, 
interleukin-1 and the tumor necrosis factor, which 
may lead to injured endothelial cells and increased 
blood coagulation and platelet aggregation [18, 
19]. It is important to note that IE differs from 
other infectious diseases owing to the presence 
of cardiac vegetations that represent an additional 
independent risk factor for embolic events. Previo-
usly, we had reported IE patients with subsequent 
embolizations with increased levels of E-selectin as 
compared to both those without emboli and healthy 
subjects [20]. This increase reflects the endothelial 
dysfunction in these patients, with induction of 
a pro-adhesive and pro-thrombotic surface causing 
a subsequent distortion of the endothelial-platelet 
axis and thrombus formation. Moreover, in the 
same population, we have found that IE patients 
with embolic events had significantly higher 
P-selectin levels, reflecting enhanced platelet 
activation, which have a direct impact on thrombus 
formation [20]. The same group of embolic patients 
also had significantly higher beta-thromboglobulin 
and platelet factor-4 levels, reflecting enhanced 
platelet activation/damage [21]. Putting these data 
together, platelet activation may play an additional 
role in thromboembolic complications of IE.
Although there has been a wide variety of diffe-
rent methods measuring platelet activity reported, 
most of them remain a research tool that are yet 
to be included in routine clinical decision-making. 
Among these, platelet volume indices are a group 
of parameters which are inexpensive, routinely 
measured by automated cell counters and easy to 
interpret. MPV and PDW are the most validated 
and prominent of these. As compared to other 
measures of platelet activity which require special 
homeostasis laboratories, blood processing proce-
dures, platelet isolation and specialized equipment, 
MPV is a practical and prognostically important 
biomarker of platelet reactivity.
Evidence derived from both retrospective and 
prospective studies suggests that increased MPV 
is an important determinant of thrombotic risk in 
predominantly arterial disorders [22–25]. Prospec-
tive studies, to a certain extent, support the value 
of elevated MPV in predicting recurrent myocardial 
infarction and death in post infarction period [26], 
impaired myocardial reperfusion after thrombolysis 
[27] or percutaneous coronary interventions in 
ST-elevation myocardial infarction [28], and re-
stenosis after stenting in angina pectoris [29, 30]. 
Larger platelets are also a characteristic feature of 
ischemic stroke, detectable from the early hours of 
its onset; probably present well before the acute 
cerebrovascular event [31]. In the literature, only 
1 study previously investigated platelet volume 
indices in IE [32]. However, the study was designed 
retrospectively in a small group of patients, and 
about one third of them had prosthetic valve endo-
carditis. None of our patients had prosthetic heart 
valves. We also excluded those being treated with 
platelet-inhibitors since a previous study reported 
reduced risk of symptomatic emboli associated 
with IE in patients who received continuous daily 
antiplatelet therapy before onset of IE [33].
Limitations of the study
A limitation of MPV as a marker of embolic 
risk is uncertainty as to whether the relation-
ship between platelet size and the event risk is 
continuous or categorical. A broad spectrum of 
MPV values was seen in our analysis, ranging 
from 7.12 to 13.4 fL. Given the significant but still 
narrow absolute difference in mean values of MPV 
between embolic and non-embolic patients, the 
clinical utility of an isolated MPV in an individual’s 
embolic risk is unclear. The MPV cut-off point 
that is most useful for predicting thromboembolic 
events in clinical practice remains unknown [10, 
22]. Another important consideration is the varia-
bility in the timing and methods of blood sample 
preparation and the type and calibration of particle 
counters, which may have had a significant impact 
in MPV measurements [8–10]. A previous study 
revealed that platelets swelled until 120 min in 
EDTA and until 60 min in citrate. There was 
a plateau of swelling after 120 min in EDTA and 
after 60 min in citrate. It was crucial to wait until 
stability of swelling had been reached. Therefore, 
they recommended that optimal measuring time 
should be 120 min after venipuncture if the tube 
containing EDTA was used [34]. In another report, 
there was an increase in MPV in EDTA within 
30 min with a mean increase of 0.7 fL, corresponding 
to a 7.9% increase over baseline. MPV, however, 
continued to increase over the 24-h period (overall 
13.4% increase) with the majority of this increase 
by 6 h (11.2%) [35]. Recently 844 articles on the 
platelet volume indeces published between 1966 
and 2011 have been reviewed [36]. In the vast 
majority of patients reviewed in this paper, blood 
samples were analyzed within 2 h of collection. All 
hematology analyzers had manufacturer-assigned 
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ranges for platelet volume indices, which differed 
significantly between different analyzers depending 
on the technology used, but no external quality as-
sessment schemes were currently available. Until 
such schemes were in place, the authors of this 
review recommended that blood samples for MPV 
should be analyzed within 2 h of venipuncture, in 
keeping with the methods used in most of the men-
tioned studies. For reliable MPV measurements, 
the potential influence of the anticoagulant must be 
carefully controlled by standardizing the time delay 
between sampling and analysis (less than 2 h). 
In our study, in order to have a standardized time 
window for the analysis, blood samples of the 
subjects were collected in the same standard tubes 
containing EDTA and analyzed immediately within 
60 min after venipuncture. Platelet activity seems 
to have a circadian variation in some reports [37], 
therefore all blood samples were drawn at 8.00 
to 10.00 a.m. Lack of laboratory standardizations 
and cut-off values along with technical problems in 
platelet volume measurements presently limit the 
widespread usefulness of platelet volume indices.
Fragmentation of valvular vegetations as 
a result of turbulent blood flow within the cardiac 
chambers is supposed to lead to systemic emboli 
in IE. However, the results of several echocardio-
graphic studies, which attempted to correlate the 
formation of an embolic event in IE with the mor-
phological characteristics of a valvular vegetations, 
have been controversial [6, 7, 38, 39]. Data are 
conflicting with regard to prognostic implications of 
vegetation characteristics such as shape, mobility 
and size for the occurrence of thromboembolic 
events. In our relatively large study population, 
although there was a trend toward a higher number 
of vegetations detected in embolic patients, this 
did not reach statistical significance. Similarly, 
location, mobility and attachment characteristics 
of vegetations were also identical in embolic and 
non-embolic groups. Not surprisingly, there was 
a significant correlation between larger vegetations 
and embolic events.
Interesting areas for future investigation in 
the field of IE are whether the reduction of MPV 
in the individual patient will lead to a change in 
thromboembolic outcome and whether a high-risk 
subgroup of patients with IE who had increased 
platelet activity reflected as elevated MPV war-
rants more aggressive treatment. It is likely that 
all therapies, including appropriate antimicrobial 
agents that lower mortality, also decrease throm-
boembolic complications. There is no information 
on the efficiency of heparin in IE; thus its use is not 
recommended because of the risk of hemorrhage, 
except for patients at perceived risk of pulmonary 
embolus or those with prosthetic heart valves. Pla-
telet-inhibitors have been of interest as adjunctive 
therapy in IE because of the integral role of plate-
lets in thromboembolic events of these patients. 
However, data on the use of platelet-inhibitors in 
IE patients to prevent major embolic events are 
insufficient [40, 41]. Aspirin was found to exert 
little, if any, effect on MPV [42]. The failure to affect 
platelet size was also reported in the case of dual 
antiplatelet (aspirin + clopidogrel) therapy [43].
Conclusions
The present study demonstrated that IE pa-
tients with embolic events had increased MPV and 
PDW values, compared to non-embolics. Future 
prospective studies with standardized measure-
ments may clarify the clinical role of platelet volu-
me indices in thromboembolic complications of IE.
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